首页> 外文期刊>Oxidative Medicine and Cellular Longevity >Artichoke Polyphenols Sensitize Human Breast Cancer Cells to Chemotherapeutic Drugs via a ROS-Mediated Downregulation of Flap Endonuclease 1
【24h】

Artichoke Polyphenols Sensitize Human Breast Cancer Cells to Chemotherapeutic Drugs via a ROS-Mediated Downregulation of Flap Endonuclease 1

机译:朝鲜蓟多酚通过ROS介导的瓣内核酸核酸酶1的下调使人乳腺癌细胞敏化为化学治疗药物1

获取原文
           

摘要

Combined treatment of several natural polyphenols and chemotherapeutic agents is more effective comparing to the drug alone in inhibiting cancer cell growth. Polyphenolic artichoke extracts (AEs) have been shown to have anticancer properties by triggering apoptosis or reactive oxygen species- (ROS-) mediated senescence when used at high or low doses, respectively. Our aim was to explore the chemosensitizing potential of AEs in order to enhance the efficacy of conventional chemotherapy in breast cancer cells. We employed breast cancer cell lines to assess the potential synergistic effect of a combined treatment of AEs/paclitaxel (PTX) or AEs/adriamycin (ADR) and to determine the underlying mechanisms correlated to this potential therapeutic approach. Our data shows that AEs/PTX reduced cell proliferation by increasing DNA damage response (DDR) mediated by Flap endonuclease 1 (FEN1) downregulation that results into enhanced breast cancer cell sensitivity to chemotherapeutic drugs. We demonstrated that ROS/Nrf2 and p-ERK pathways are two molecular mechanisms involved in the synergistic effect of AEs plus PTX treatment. To highlight the role of ROS herein, we report that the addition of antioxidant N-acetylcysteine (NAC) significantly decreased the antiproliferative effect of the combined treatment. A combined therapy could be able to reduce the dose of chemotherapeutic drugs, minimizing toxicity and side effects. Our results suggest the use of artichoke polyphenols as ROS-mediated sensitizers of chemotherapy paving the way for innovative and promising natural compound-based therapeutic strategies in oncology.
机译:结合几种天然多酚和化学治疗剂的处理更有效地与单独的药物相比,仅在抑制癌细胞生长中。通过分别在高剂量或低剂量使用时,已经显示通过触发凋亡或反应性氧物质 - (ROS-)介导的衰老具有抗癌性能的多酚朝鲜蓟提取物(AES)。我们的目标是探讨AES的化学敏感潜力,以提高常规化疗在乳腺癌细胞中的疗效。我们使用乳腺癌细胞系来评估AES / PACLITAXEL(PTX)或AES / ADRIAMYCIN(ADR)的组合治疗的潜在协​​同效应,并确定与该潜在治疗方法相关的潜在机制。我们的数据表明,AES / PTX通过增加由翻盖内切核酸酶1(FEN1)介导的DNA损伤响应(DDR)降低细胞增殖,从而降低导致增强乳腺癌细胞对化学治疗药物的敏感性。我们证明ROS / NRF2和P-ERK途径是AES加PTX治疗的协同效应的两个分子机制。为了突出在本文中的RO的作用,我们报告说,添加抗氧化N-乙酰半胱氨酸(NAC)显着降低了组合治疗的抗增殖作用。组合治疗可以能够减少化学治疗药物的剂量,最小化毒性和副作用。我们的研究结果表明,使用朝鲜蓟多酚作为罗斯介导的化疗敏感剂,为肿瘤学中的创新和有前途的自然化合物的治疗策略铺平了途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号